Keymed Biosciences Inc. (HKG:2162)
Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
54.80
+3.70 (7.24%)
Mar 10, 2026, 2:44 PM HKT

Keymed Biosciences Ratios and Metrics

Millions HKD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019
Period Ending
Mar '26 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
Market Capitalization
15,0548,51613,58614,1749,651-
Upgrade
Market Cap Growth
56.74%-37.32%-4.15%46.87%--
Upgrade
Enterprise Value
12,9476,52610,72510,33115,170-
Upgrade
Last Close Price
51.1030.9049.1051.0034.50-
Upgrade
PS Ratio
15.7518.6934.83125.3071.30-
Upgrade
PB Ratio
4.303.234.133.762.16-
Upgrade
P/TBV Ratio
4.313.254.133.762.15-
Upgrade
EV/Sales Ratio
13.5514.3227.4991.33112.08-
Upgrade
Debt / Equity Ratio
0.270.300.140.040.01-1.33
Upgrade
Net Debt / Equity Ratio
-0.60-0.57-0.77-0.91-0.96-1.00
Upgrade
Net Debt / EBITDA Ratio
6.652.555.675.8510.02-8.13
Upgrade
Net Debt / FCF Ratio
2.251.413.374.499.02-7.89
Upgrade
Asset Turnover
0.210.110.090.030.05-
Upgrade
Inventory Turnover
0.320.130.660.071.02-
Upgrade
Quick Ratio
3.663.048.808.4531.554.42
Upgrade
Current Ratio
3.953.309.368.7231.964.75
Upgrade
Return on Equity (ROE)
-8.82%-18.85%-11.31%-8.69%-305.24%-
Upgrade
Return on Assets (ROA)
-5.44%-10.23%-7.32%-8.65%-10.09%-15.67%
Upgrade
Return on Capital Employed (ROCE)
-9.60%-20.70%-12.80%-15.30%-9.40%-33.10%
Upgrade
Earnings Yield
-1.87%-6.44%-2.91%-2.46%-49.44%-
Upgrade
FCF Yield
-6.22%-12.46%-5.53%-5.43%-4.92%-
Upgrade
Buyback Yield / Dilution
-0.70%-0.22%-0.09%-62.34%-139.72%-
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.